**NSE/BSE SME Listed | (Formerly Fabino Life Sciences Limited)** Fabino Enterprises Limited is an Indian pharmaceutical and wellness company currently undergoing a strategic transformation into a diversified FMCG and agro-business conglomerate. Listed on the **BSE SME platform** since **January 13, 2022**, the company is pivoting from a pure-play pharmaceutical marketing firm to an integrated player across healthcare, biotechnology, food processing, and agricultural sectors. --- ### **Strategic Pivot: From Life Sciences to Multi-Sector Enterprise** In **March 2024**, the company officially rebranded from **Fabino Life Sciences Limited** to **Fabino Enterprises Limited**. This change reflects a fundamental shift in the company’s "Main Objects" clause, expanding its operational mandate to include: * **Agro-Business & Veterinary:** Manufacturing and trading of **fertilizers, pesticides, herbicides, and plant growth regulators**, alongside **animal health products** and **veterinary medicines**. * **Food Processing:** Processing, canning, and marketing of **edible powders, juices, spices, pickles, and table delicacies**. * **Biotechnology:** Research and development in **Genetically Modified Organisms (GMOs)**, **vaccines**, and **immunobiological substances**. * **Agriculture & Horticulture:** Direct involvement in the cultivation and trading of fresh and preserved produce, including **herbs and medicinal plants**. --- ### **Core Business Model & Manufacturing Ecosystem** Fabino operates a hybrid model that balances in-house production with scalable third-party partnerships to manage a portfolio of over **70 active products**. * **Brand Portfolio:** * **Fabino:** The flagship brand for **Pharmaceuticals**, covering **Allopathic** and **Herbal** ranges including **Tablets, Ointments, and Syrups**. * **Keepshine:** A dedicated **Personal Care** brand focusing on **shampoos** and hair maintenance products. * **Operational Infrastructure:** * **Primary Processing Center:** Located in **Sonipat, Haryana**. * **Loan Licensing:** Ayurvedic formulations are produced via **Schedule T** (Drugs & Cosmetics Rules, 1945) approved facilities. * **Contract & Third-Party Manufacturing:** Utilizes dedicated facilities in **Haryana** and external partners for made-to-order product ranges. * **Distribution:** Employs an internal sales force and a proprietary network to reach domestic markets and international territories like **Nepal**. --- ### **Financial Performance & Capital Structure** The company has shown a significant surge in standalone revenue, though consolidated figures reflect the costs of ongoing diversification and subsidiary integration. **Key Financial Metrics (FY 2024-25)** | Metric | Consolidated | Standalone | | :--- | :--- | :--- | | **Total Income** | **₹18.33 Crore** | **₹18.32 Crore** | | **Net Profit (PAT)** | **₹6.11 Lakhs** | **₹13.19 Lakhs** | | **Revenue Growth (YoY)** | **-13%** | **+201%** | | **Profit Growth (YoY)** | **+70.6%** | **+177%** | **Capital & Shareholding Data** * **Authorized Share Capital:** **₹12,00,00,000** * **Paid-up Capital:** **₹2,10,00,000** (2,100,000 Equity Shares at ₹10 each) * **Promoter Holding:** **Atul Jain** and **Aditya Mahavir Jain** collectively hold **104.76%** of the voting rights (each holding **1,100,000 shares** or **52.38%**). * **Securities Premium:** **₹185.40 Lakhs**. * **Surplus (P&L):** Increased to **₹25.13 Lakhs** (up from ₹19.02 Lakhs). --- ### **Expansion Strategy & Growth Catalysts** Management is aggressively positioning the company to capitalize on the **US$ 130 billion** projected Indian pharma market by **2030** and the growing demand for low-cost generics. 1. **Working Capital Augmentation:** The company is focused on increasing its "order-taking appetite" by securing liquid funds to support its capital-intensive business model. 2. **Subsidiary Integration:** The wholly-owned subsidiary, **Upender Metaplast Private Limited** (incorporated **March 2023**), is a key component of the group's expanded manufacturing and operational footprint. 3. **Investment Mandate:** Shareholders have authorized an investment/loan limit of up to **₹10 Crore** under Section 186 to facilitate strategic acquisitions or corporate investments. 4. **Digital Transformation:** Transitioning customer engagement and vendor management to **e-commerce** and **social media** platforms. 5. **Geographic Reach:** Strengthening presence in **North India** (Haryana, Delhi, Punjab), **East India** (UP, Orissa, WB), and **South India** (Andhra Pradesh). --- ### **Market Context & Regulatory Alignment** Fabino is aligning its portfolio with several high-growth government initiatives and industry trends: | Initiative | Sector Impact | | :--- | :--- | | **Bulk Drug Parks** | **₹1,000 Crore** allocation for FY25; supports raw material security. | | **Jan Aushadhi Scheme** | Budget increased to **₹284.5 Crore**; drives demand for generics. | | **Pharmerging Markets** | **5-8%** expected spending growth through 2027. | | **FDI Policy** | **100% FDI** permitted for Greenfield pharma, easing capital entry. | --- ### **Risk Profile & Mitigation Framework** The company operates in a high-stakes environment characterized by regulatory volatility and intense competition. * **Regulatory Compliance:** Constant pressure to meet **USFDA** and **GMP** standards. Any shift in the **Uniform Code of Pharmaceutical Marketing Practices (UCPMP)** could impact doctor-engagement strategies. * **Pricing & Margins:** Government mandates on drug price caps and potential **GST** rationalization (currently **12%**) pose risks to profitability. * **Cyber Security:** As the industry becomes a primary target for data breaches (average cost **$4.82 million**), the company is investing in digital safeguards. * **Operational Risks:** Managed through the **Audit Committee**, focusing on supply chain resilience (moving toward **circular models**) and talent retention in a market with high demand for technical expertise. * **Financial Stability:** While the company has reported **no cash losses** and maintains the ability to meet short-term liabilities, it remains exposed to **currency fluctuations** and **interest rate risks**.